Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management
World J Gastroenterol. 2024 Apr 7;30(13):1780-1790. doi: 10.3748/wjg.v30.i13.1780.ABSTRACTColorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may ...
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Katsuhiro Kita Allen Burdowski Source Type: research
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions
World J Gastroenterol. 2024 Apr 7;30(13):1815-1835. doi: 10.3748/wjg.v30.i13.1815.ABSTRACTColorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes. Despite considerable progress in development of CRC therapeutics, challenges remain regarding the diagnosis and management of advanced stage metastatic CRC (mCRC). In particular, the five-year survival rate is very low since mCRC is currently rarely curable. Over the past decade, cancer treatment has significantly improved with the introduction of cancer immunotherapies, specifically immune checkpoint inhibitors. Therapies aimed at blocking imm...
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Samantha Sharma Naresh Singh Anita Ahmed Turk Isabella Wan Akshay Guttikonda Julia Lily Dong Xinna Zhang Mateusz Opyrchal Source Type: research
Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: Unravelling challenges and future directions
World J Gastroenterol. 2024 Apr 7;30(13):1815-1835. doi: 10.3748/wjg.v30.i13.1815.ABSTRACTColorectal cancer (CRC) is a complex disease with diverse etiologies and clinical outcomes. Despite considerable progress in development of CRC therapeutics, challenges remain regarding the diagnosis and management of advanced stage metastatic CRC (mCRC). In particular, the five-year survival rate is very low since mCRC is currently rarely curable. Over the past decade, cancer treatment has significantly improved with the introduction of cancer immunotherapies, specifically immune checkpoint inhibitors. Therapies aimed at blocking imm...
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Samantha Sharma Naresh Singh Anita Ahmed Turk Isabella Wan Akshay Guttikonda Julia Lily Dong Xinna Zhang Mateusz Opyrchal Source Type: research
Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management
World J Gastroenterol. 2024 Apr 7;30(13):1780-1790. doi: 10.3748/wjg.v30.i13.1780.ABSTRACTColorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may ...
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Katsuhiro Kita Allen Burdowski Source Type: research
Perfusion drugs for non ‑muscle invasive bladder cancer (Review)
Oncol Lett. 2024 Apr 15;27(6):267. doi: 10.3892/ol.2024.14400. eCollection 2024 Jun.ABSTRACTThe high recurrence rate and poor prognosis of non-muscle invasive bladder cancer (BC) are challenges that need to be urgently addressed. Transurethral cystectomy for bladder tumors is often combined with bladder perfusion therapy, which can effectively reduce the recurrence and progression rates of BC. The present review integrated and analyzed currently available bladder perfusion drugs, mainly including chemotherapeutic agents, immunotherapeutic agents and other adjuvant perfusion drugs. Bacillus Calmette-Guerin (BCG) perfusion w...
Source: Oncology Letters - April 25, 2024 Category: Cancer & Oncology Authors: Jingyuan Qian Qiuchen Zhang Yang Cao Xi Chu Yiyang Gao Haifei Xu Hongzhou Cai Jiajia Wu Source Type: research
Recent clinical trials and optical control as a potential strategy to develop microtubule-targeting drugs in colorectal cancer management
World J Gastroenterol. 2024 Apr 7;30(13):1780-1790. doi: 10.3748/wjg.v30.i13.1780.ABSTRACTColorectal cancer (CRC) has remained the second and the third leading cause of cancer-related death worldwide and in the United States, respectively. Although significant improvement in overall survival has been achieved, death in adult populations under the age of 55 appears to have increased in the past decades. Although new classes of therapeutic strategies such as immunotherapy have emerged, their application is very limited in CRC so far. Microtubule (MT) inhibitors such as taxanes, are not generally successful in CRC. There may ...
Source: Cancer Control - April 25, 2024 Category: Cancer & Oncology Authors: Katsuhiro Kita Allen Burdowski Source Type: research
Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The ...
Source: Rheumatic Disease Clinics of North America - April 25, 2024 Category: Rheumatology Authors: David F.L. Liew, Sarah L. Mackie, Alice Tison, Sebastian E. Sattui, Max Yates, Russell R.C. Buchanan, Claire E. Owen Source Type: research
---
David Liew and Alexa Meara have provided an issue and toolbox that are not only current state-of-the-art but also clearly required for the field to move forward. Rheumatic immune –related adverse events need to be understood and addressed by all Rheumatologists (not just a few in limited centers) because the success story of immune checkpoint inhibitor immunotherapy is growing and certainly is associated with meaningful health care results. One of the most important outcom es from this issue is our experts, who put the articles together, now can tell us how to diagnose and manage these events and provide quality care. (S...
Source: Rheumatic Disease Clinics of North America - April 25, 2024 Category: Rheumatology Authors: Michael H. Weisman Tags: Foreword Source Type: research
Mutation of neurotrophic tyrosine receptor kinase can promote pan-cancer immunity and the efficacy of immunotherapy
The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis t... (Source: Molecular Cancer)
Source: Molecular Cancer - April 25, 2024 Category: Cancer & Oncology Authors: Congren Wang, Yingying Li, Jinyuan Huang, Huimeng Yan and Bin Zhao Tags: Correspondence Source Type: research
Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review
AbstractCopper is a necessary micronutrient for maintaining the well-being of the human body. The biological activity of organic ligands, especially their anticancer activity, is often enhanced when they coordinate with copper(I) and (II) ions. Copper and its compounds are capable of inducing tumor cell death through various mechanisms of action, including activation of apoptosis signaling pathways by reactive oxygen species (ROS), inhibition of angiogenesis, induction of cuproptosis, and paraptosis. Some of the copper complexes are currently being evaluated in clinical trials for their ability to map tumor hypoxia in vari...
Source: Journal of Cancer Research and Clinical Oncology - April 25, 2024 Category: Cancer & Oncology Source Type: research
An endothelial-related prognostic index for bladder cancer patients
ConclusionWe have effectively discerned pivotal genes from the endothelial cell perspective and constructed an EPI for BC patients, thereby offering promising prospects for precision medicine. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 25, 2024 Category: Cancer & Oncology Source Type: research
Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication
Immunotherapy has emerged as a potent clinical approach for cancer treatment, but only subsets of cancer patients can benefit from it. Targeting lactate metabolism (LM) in tumor cells as a method to potentiate... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - April 25, 2024 Category: Cancer & Oncology Authors: Dongjie Chen, Pengyi Liu, Xiongxiong Lu, Jingfeng Li, Debin Qi, Longjun Zang, Jiayu Lin, Yihao Liu, Shuyu Zhai, Da Fu, Yuanchi Weng, Hongzhe Li and Baiyong Shen Tags: Research Source Type: research
Cancers, Vol. 16, Pages 1655: Real-World Treatment Patterns and Survival Outcomes for Patients with Non-Metastatic Non-Small-Cell Lung Cancer in Sweden: A Nationwide Registry Analysis from the I-O Optimise Initiative
aker
Gunnar Wagenius
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, with ~40–50% of patients diagnosed with non-metastatic disease (stages IA–IIIC). The treatment landscape is evolving rapidly as immunotherapies and targeted therapy are introduced in the non-metastatic setting, creating a need to assess patient outcomes prior to their introduction. This real-world study using Swedish National Lung Cancer Registry data examined outcomes (overall survival (OS) and time to next treatment or death (TTNTD)) and treatment patterns for adults diagnosed ...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Gudrun N. Oskarsdottir Erik Lampa Anders Berglund Linda Rosengren Maria Ulvestad Miklos Boros Melinda J. Daumont Caroline Rault Gabrielle Emanuel C átia Leal Minouk J. Schoemaker Gunnar Wagenius Tags: Article Source Type: research
Cancers, Vol. 16, Pages 1663: Outcomes and Adverse Events in Patients with Cancer after Diagnosis of Immunotherapy-Associated Diabetes Mellitus: A Retrospective Cohort Study
Quandt
Immune checkpoint inhibitor (CPI)-induced diabetes mellitus (CPI-DM) is a rare immune-related adverse event (irAE). Patients and providers fear that continuing CPIs puts patients at risk for additional irAEs and thus may discontinue therapy. Currently, there are little data to inform this decision. Therefore, this study aims to elucidate whether discontinuing CPIs after diagnosis of CPI-DM impacts the development of future irAEs and cancer outcomes such as progression and death. Patients who developed CPI-DM during cancer treatment at UCSF from 1 July 2015 to 5 July 2023 were analyzed for cancer outcomes and...
Source: Cancers - April 25, 2024 Category: Cancer & Oncology Authors: Duvalyan Brondfield Rushakoff Anderson Quandt Tags: Article Source Type: research
Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study
AbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a highly immunosuppressive microenvironment. This single-blind, randomized study aimed to evaluate the synergistic immunomodulatory effects of synbiotics (probiotics and inulin prebiotics), as well as their impact on postoperative complications and outcomes, compared to the use of probiotics alone. Ninety patients diagnosed with PDAC were enrolled and randomly assigned into three groups: the placebo group, the probiotics group (receiving a mixture of ten strains of Lactobacillus, Bifidobacterium, and Streptococcus bacteria at a dose of 25 billion ...
Source: Cancer Immunology, Immunotherapy - April 25, 2024 Category: Cancer & Oncology Source Type: research
